RENB Renovaro Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RENB

Price (delayed)

$1.5

Market cap

$215.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.7

Enterprise value

$222.65M

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and ...

Highlights
The company's EPS has surged by 66% YoY
Renovaro Biosciences's net income has soared by 62% YoY
Renovaro Biosciences's quick ratio has shrunk by 72% YoY and by 38% QoQ
The debt has surged by 61% since the previous quarter and by 5% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: https://enochianbio.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of RENB
Market
Shares outstanding
143.67M
Market cap
$215.5M
Enterprise value
$222.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$40.38M
EBITDA
-$40.26M
Free cash flow
-$11.54M
Per share
EPS
-$0.7
Free cash flow per share
-$0.18
Book value per share
$0.65
Revenue per share
$0
TBVPS
$0.06
Balance sheet
Total assets
$58.02M
Total liabilities
$14.42M
Debt
$7.39M
Equity
$43.6M
Working capital
-$11.36M
Liquidity
Debt to equity
0.17
Current ratio
0.17
Quick ratio
0.1
Net debt/EBITDA
-0.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-65.3%
Return on equity
-81.3%
Return on invested capital
N/A
Return on capital employed
-91.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RENB stock price

How has the Renovaro Biosciences stock price performed over time
Intraday
0.67%
1 week
-1.96%
1 month
-45.85%
1 year
25%
YTD
-52.68%
QTD
-43.4%

Financial performance

How have Renovaro Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.15M
Net income
-$41.23M
Gross margin
N/A
Net margin
N/A
RENB's operating income has soared by 65% YoY
Renovaro Biosciences's net income has soared by 62% YoY

Growth

What is Renovaro Biosciences's growth rate over time

Valuation

What is Renovaro Biosciences stock price valuation
P/E
N/A
P/B
2.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 66% YoY
The equity has declined by 35% year-on-year and by 7% since the previous quarter
The stock's P/B is 34% above its 5-year quarterly average of 1.7 but 24% below its last 4 quarters average of 3.0

Efficiency

How efficient is Renovaro Biosciences business performance
The ROA has grown by 36% YoY but it has contracted by 9% from the previous quarter
RENB's ROE is up by 31% year-on-year but it is down by 12% since the previous quarter

Dividends

What is RENB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RENB.

Financial health

How did Renovaro Biosciences financials performed over time
Renovaro Biosciences's quick ratio has shrunk by 72% YoY and by 38% QoQ
The current ratio has plunged by 65% YoY and by 11% from the previous quarter
The debt is 83% smaller than the equity
The debt to equity has soared by 70% since the previous quarter and by 70% year-on-year
The debt has surged by 61% since the previous quarter and by 5% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.